Incarceration experiences in a cohort of active injection drug users

Drug and Alcohol Review

Volumn 27, Issue 6, 2008, Pages 693-699

  Milloy, M J ^a   Wood, Evan ^a,b   Small, Will ^a   Tyndall, Mark ^a,b   Lai, Calvin ^a   Montaner, Julio ^a,b   Kerr, Thomas ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

GEE; HIV; IDU; Incarceration; Injection drug users

Indexed keywords

ADDICTION; ADULT; AGE; ARTICLE; CANADA; COHORT ANALYSIS; DRUG ABUSE; FEMALE; HARM REDUCTION; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAW ENFORCEMENT; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; PREVALENCE; PRISONER; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; SUBSTANCE ABUSE;

ADULT; AGE FACTORS; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; HARM REDUCTION; HEPATITIS C; HIV INFECTIONS; HUMANS; LAW ENFORCEMENT; MALE; MULTIVARIATE ANALYSIS; NEEDLE SHARING; PREVALENCE; PRISONERS; QUESTIONNAIRES; RISK FACTORS; RISK-TAKING; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 56749170433     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230801956157     Document Type: Article

References (62)

1. Kerr T, Wood E, Grafstein E, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) 2005;27:62-6.
2. Spittal PM, Hogg RS, Li K, et al. Drastic elevations in mortality among female injection drug users in a Canadian setting. AIDS Care 2006;18:101-8.
3. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. Aids 1997;11:F59-65.
4. Thomas K. Female injection drug users in Vancouver face higher risks of HIV infection. Can HIV AIDS Policy Law Rev 2002;7:36.
5. Beyrer C, Jittiwutikarn J, Teokul W, et al. Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS Behav 2003;7:153-61.
6. Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former injection drug users report of HIV risk behaviors during periods of incarceration. Subst Abuse 2001;22: 209-16.
7. Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among streetrecruited injection drug users in Los Angeles County, 1994-1996. Addiction 2001;96:589-95.
8. Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999; 15:699-704.
9. Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: Results of a national cross sectional survey. BMJ 2000 8;321:78-82.
10. Malliori M, Sypsa V, Psichogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 1998;93:243-51.
11. Shewan D, Gemmell M, Davies JB. Behavioural change amongst drug injectors in Scottish prisons. Soc Sci Med 1994;39:1585-6.
12. Darke S, Kaye S, Finlay-Jones E. Drug use and injection risk-taking among prison methadone maintenance patients. Addiction 1998;93:1169-75.
13. Small W, Kain S, Laliberte N, Schechter MT, O'Shaughnessy MV, Spittal PM. Incarceration, addiction and harm reduction: Inmates experience injecting drugs in prison. Subst Use Misuse 2005;40:831-43.
14. Calzavara LM, Burchell AN, Schlossberg J, et al. Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction 2003;98:1257-65.
15. Choopanya K, Des Jarlais DC, Vanichseni S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr 2002;29:86-94.
16. Rotily M, Weilandt C, Bird SM, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Public Health 2001; 11:243-50.
17. Strang J, Gossop M, Heuston J, Green J, Whiteley C, Maden A. Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. Addiction 2006;101:1125-32.
18. Dolan K. The epidemiology of hepatitis C infection in prison populations. In: Commonwealth Department of Health and Aged Care. Hepatitis C: Informing Australia's national response. Canberra: Commonwealth Department of Health and Aged Care, 2000:61-93.
19. Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction 2000;95:1207-16.
20. Hankins CA, Gendron S, Handley MA, Richard C, Tung MT, O'Shaughnessy M. HIV infection among women in prison: An assessment of risk factors using a nonnominal methodology. Am J Public Health 1994;84:1637-40.
21. Jurgens R. HIV/AIDS in prisons: New developments. Canadian HIV/AIDS Policy Law Newslett 1999;4:61-6.
22. Ford PM, Pearson M, Sankar-Mistry P, Stevenson T, Bell D, Austin J. HW, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. Q J Med 2000;93: 113-19.
23. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004;94:1218-23.
24. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HPV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: A national survey. Commun Dis Public Health 2000;3:121-6.
25. Beyrer C. HIV epidemiology update and transmission factors: Risks and risk contexts. XVI International AIDS Conference, Toronto, Canada, 14 August 2006.
26. Correctional Services Canada. Infection disease prevention and control in Canadian federal penitentiaries. Ottawa: The Government of Canada, 2003.
27. Millson P, Myers T, Rankin J, et al. Prevalence of human immunodeficiency virus and associated risk behaviour in injection drug users in Toronto. Can J Public Health 1995;86:176-80.
28. Mahon N. New York inmates' HIV risk behaviors: The implications for prevention policy and programs. Am J Public Health 1996;86:1211-15.
29. Correctional Service of Canada (CSC). Correctional Service of Canada (CSC) action plan in response to the report of the Canadian Human Rights Commission. Ottawa: The Government of Canada, 2005.
30. Correctional Services Canada. Response from the Correctional Service of Canada to the 33rd Annual Report of the Correctional Investigator (2005-2006). Ottawa: The Government of Canada, 2006.
31. Kondro W. Conservative government scuttles needle exchange. Can Med Assoc J 2007;176:308.
32. The attorney-general of Canada. National anti drug strategy: Backgrounder. Ottawa: The Government of Canada, 2007.
33. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids 2003;17:887-93.
34. Hagan H. The relevance of attributable risk measures to HIV prevention planning. Aids 2003;17:911-13.
35. Kerr T, Wood E, Small D, Palepu A, Tyndall MW. Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. Can Med Assoc J 2003;169:759-63.
36. Wood E, Kerr T, Buchner C, Marsh D, Montaner J, Tyndall M. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J 2004;1:9.
37. Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug Alcohol Depend 2006;83:193-8.
38. Kerr T, Fairbairn N, Tyndall MW, et al. Predictors of non-fatal overdose among a cohort of polysubstanceusing injection drug users. Drug Alcohol Depend 2007: 39-45.
39. Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users (Washington, DC: 1974). Public Health Rep 2005:150-6.
40. Calzavara LM, Burchell AN, Schlossberg J, et al. Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction 2003:1257-65.
41. Wood E, Tyndall MW, Spittal PA, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injecting rooms help? Can Med Assoc J 2001;165:405-10.
42. Lee JH, Herzog TA, Meade CD, Webb MS, Brandon TH. The use of GEE for analyzing longitudinal binomial data: a primer using data from a tobacco intervention. Addict Behav 2007;32:187-93.
43. Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend 2006;83:147-56.
44. Boe R, Nafekh M, Vuong B, Sinclair R, Cousineau C. The changing profile of the Federal inmate population: 1997 to 2002. Ottawa: The Government of Canada, 2003.
45. Aboriginal Issues Branch, Correctional Services of Canada. Demographic overview of Aboriginal peoples in Canada and Aboriginal offenders in Federal corrections. Ottawa: The Government of Canada, 1999.
46. Dufour A, Alary M, Poulin C, et al. Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City. Aids 1996;10:1009-15.
47. Hall J, et al. A breeding ground for communicable disease; needle exchange program urged; HIV affects 2% of adult inmates. Toronto Star, 16 August 2006;Sect. 6.
48. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005;366:316-18.
49. United Nations General Assembly. High Commissioner for Human Rights, Basic principles for the treatment of prisoners. Geneva: Office of the United Nations, 1990.
50. The Parliament of Canada. Corrections and Conditional Release Act. C-44. Ottawa: The Parliament of Canada, Non-Medical Uses of Drugs, 1992.
51. House of Commons Special Committee on Policy for the new millennium: Working together to redefine Canada's drug strategy. Ottawa: The Parliament of Canada, 2002.
52. Canadian Human Rights Commission. Protecting their rights: A systemic review of human rights in correctional services for federally sentenced women. Ottawa: The Parliament of Canada, 2003.
53. House of Commons Standing Committee on Health. Strengthening the Canadian strategy on HIV/AIDS. Ottawa: The Parliament of Canada, 2003.
54. Ontario Medical Association. Improving our health: Why is Canada lagging behind in establishing needle exchange programs in prison? Toronto, Ontario: Ontario Medical Association, 2004.
55. Correctional Investigator of Canada. Annual report. Ottawa: The Parliament of Canada, 2006.
56. Kerr T, Wood E, Betteridge G, Lines R, Jürgens R. Harm reduction in prisons: A 'rights based analysis'. Crit Public Health 2004;14:345-60.
57. Lines R, Jürgens R, Betteridge G, Stöver H, Laticevschi D, Nelles J. Prison needle exchange: Lessons from a comprehensive review of international evidence and experience. Montreal, Quebec: Canadian HIV/AIDS Legal Network, 2006.
58. Dolan K, Rutter S, Wodak A. Prison-based syringe-exchange programmes: A review of international research and development. Addiction 2003;98:153-8.
59. Wong T, Archibald C, Arthur J, et al. Prison needle exchange: Review of the evidence. Ottawa: Public Health Agency of Canada, 2006.
60. Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep 2005;120:150-6.
61. Tyndall MW, Wood E, Zhang R, Lai C, Montaner JS, Kerr T. HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: Implications for prevention, care and treatment. Harm Reduct J 2006;3:36.
62. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. Lancet 1999;353:1657-61.